Free Newsletter
FDA reviewing Botox adverse reports
Even de-fanged botulinum toxin may still be toxic to some people. The FDA says patients taking Botox and its sister med Myobloc have exhibited serious health problems, including muscle paralysis and death. The meds, which are best known for smoothing wrinkles, also are used to combat other muscle-related maladies. The agency says it's reviewing the meds' safety, but it so far hasn't pinned down a causal relationship between the products and the safety problems.
Most of the severe reactions occurred in children treated for limb spasicity associated with cerebral palsy. Strangely, the symptoms resemble botulism, a paralyzing illness caused by botulinum toxin in food.
The FDA's review comes two weeks after Public Citizen, a consumer activist organization, petitioned the agency to warn doctors and patients of serious side effects. The group said it found 180 serious adverse events in FDA records; the agency, however, says it's received fewer than 100 reports.
- read the FDA's release
- see the story in USA Today
- find this piece in the Financial Times
Related Article:
HealthCanada to review Botox safety. Report
Comments
Post new comment
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession






SHARE
WITH: